Prospective Evaluation Of Outcomes For Patients Undergoing Radiofrequency Ablation (RFA) Using HALO Ultra Device For Gastric Antral Vascular Ectasia (GAVE)

Withdrawn before enrolling

Conditions studied: Gastric Antral Vascular Ectasia

In brief

The purpose: To determine the safety and efficacy of Radiofrequency Ablation (RFA) HALO Ultra system in patients with Gastric Antral Vascular Ectasia patient cohort (GAVE). Research design: This is a prospective observational study. Procedure Used: Radiofrequency Ablation Risks and potential benefits: There are no risks associated with this study as it is a retrospective chart review. Potential benefits include the knowledge gained from this study which may be of help to patients in the future. Importance of knowledge that may reasonably be expected to result The knowledge gained from this study may be of help to other patients in the future.

Key facts

Study ID

NCT03525366

Run by

The University of Texas Health Science Center, Houston

People needed

0

Starts

2015-08-01

Expected to finish

2025-12-01

Last updated by the study team

2025-08-17

Who can join

Age: 18 and older, up to 100. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• In-patients
• Patients diagnosed with GAVE
• Patients undergoing radiofrequency ablation with HALO ULTRA device

You may not qualify if…

• Patients who were not diagnosed with GAVE
• Patients undergoing RFA with HALO ULTRA device for diseases other than GAVE.
• Patients with GAVE receiving other endoscopic therapies like argon plasma coagulation (APC) or radiofrequency ablation (RFA) with devices other than HALO ULTRA

Where it is running

• Memorial Hermann Hospital — Houston, Texas, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.